Intellia, Regeneron highlight clinical results for CRISPR-Cas9 gene therapy

By Samantha Black, PhD, ScienceBoard editor in chief

June 28, 2021 -- Intellia Therapeutics and Regeneron Pharmaceuticals have announced positive interim data from an ongoing phase I study of their in vivo candidate, NTLA-2001, as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim results support the clinical efficacy and safety of in vivo CRISPR genome editing therapy in humans.

The interim data were published in the New England Journal of Medicine on June 26 and are drawn from a study of the first six patients across two single-ascending dose cohorts in the U.K. and New Zealand. Treatment with NTLA-2001 led to dose-dependent reductions in serum TTR, with mean reductions of the protein ranging from 52% in a low-dose group (0.1 mg/kg) to 87% in a higher-dose group (0.3 mg/kg). NTLA-2001 was generally well tolerated, with no serious adverse events.

The companies will continue to evaluate NTLA-2001 at a higher dosage as part of the dose-escalation portion of the study to determine if a higher dose could result in a deeper reduction in protein levels leading to the potential for more meaningful clinical benefit. The third cohort, evaluating NTLA-2001 at the 1 mg/kg-dose level, is actively enrolling participants.

Following the identification of a recommended dose, Intellia expects to begin a single-dose expansion cohort in part two of the phase I trial later this year. After completion of the phase I trial, the company plans to study NTLA-2001 for both polyneuropathy and cardiomyopathy manifestations of ATTR amyloidosis.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here